

NEW TRACK FOR VISION CARE

NovaSight's vision is to bring pediatric vision care into the digital age

Our mission is to prevent pediatric vision loss by integrating cutting-edge **EYE-TRACKING** technology into innovative solutions which are specially designed to suit the unique needs and attention spans of children

THE UNMET NEED > Traditional Vision Assessment and Treatment Methods Fall Short

THE VISION ASSESSMENT tests that hundreds of millions of children worldwide undergo every year are not sufficiently effective to detect many visual impairments, including lazy eye, with the result that these conditions often go undetected or are misdiagnosed

LAZY EYE affects 3.5% of the population worldwide, putting the patients at risk for vision loss. The current gold standard treatment of putting a patch over the strong eye results in a loss of 3D vision and suffers from low patient compliance (below 50%). Children who are not diagnosed or treated on time, may suffer from permanent vision loss

OUR TECHNOLOGY > Cutting Edge Digital Innovation



EYE-TRACKING - Sensors track and record the momentary gaze position, sampling eye movements 90 times per second



ACTIVESIGHT™ TECHNOLOGY - NovaSight's proprietary 3D active shutter glasses with remote control eye occlusion, distance and tilt measurements

OUR SOLUTIONS > End-to-End Pediatric Vision Care



eyeswift VISION ASSESSMENT

While the patient watches short videos, EyeSwift® performs fast and accurate assessment to numerous vision impairments



curesight LAZY-EYE TREATMENT

The CureSight™ is an amblyopia (lazy-eye) treatment system for home use. The treatment process is carried out while the child watches a video of choice in the comfort of their home

GO-TO-MARKET

EyeSwift®

Signed OEM agreement with the largest vision care corporate in the world with access to 500,000 eye-care givers globally. ASP of \$2,500.

CureSight™

Reimbursement process in the US to be completed by 2021, reaching coverage from 50% of buyers. Monthly fee of \$250.

INVESTMENT OPPORTUNITY

Significant return on investment

NovaSight offers extremely quick time-to-market and a large potential return on investment.

EyeSwift® system - sales will start in Q2' 2019.

We expect to get FDA approval for the CureSight™ system in Q1' 2019, with sales starting in Q2' 2019..

NOVASIGHT IN NUMBERS

- Established in 2016
- 15 employees
- 1 patent granted, 7 patents pending
- Potential market value of \$5 billion
- Funds raised - \$6.5 million
- Round target - \$5-\$8 million

FOUNDERS

Extensive industry experience with proven track record

Ran Yam, CEO

Former VP R&D for Visionix, developed products achieving annual sales exceeding \$50M.

Dan Oz, CTO

Former co-founder of Sightline sold to Stryker for \$50M.

Prof. Michael Belkin, CMO

Inventor and former CMO of Optonol, sold to Alcon for \$200M